Stephanie supervises PhD and MSc students on a regular basis. Academically she has attended the supervisor course and received the Post-Graduate Certificate for Higher Education (PGCHE). She is also a qualified First Aider for the John van Geest Cancer Research Centre.
She reviews original papers for journals such as Cancer Immunotherapy and Immunology, European Journal of Cancer, Cancer Therapy, vaccine supplement and Medicinal Chemistry and Amino-Acid. She also reviews grant proposals and writes grants. She has established many collaborations with national and international laboratories.
She oversaw an International project involving nine laboratories and presented the results at the European Society of cancer and immunotherapy (ESCII) conference held in Athens, Oct. 2008. She has organised two ELISPOT workshops and helped organised PIVAC12 conference which were all great successes.
She is also regularly invited to give seminars in the UK and in Europe about the work that she is leading at the John van Geest Cancer Research Centre.
1995-1999: PhD: Hallamshire Hospital, Medical School, Sheffield.
1993-1995: B.Sc (Hons 2.1), Metropolitan University of Manchester.
The John van Geest Cancer Research Centre, lead by Prof. Graham A. Pockley is focused on improving the diagnosis, prognosis and treatment of prostate, and breast cancer as well as Glioblastoma (GBM).
The Centre has an exceptional number of experts and state of the art technologies which allow it's scientists to interrogate in great depth markers expressed on either on the surface of immune cells (10 colours flow cytometry) or by immune cells (nanoString) as well as assess their function (Flow cytometry sorting machine MoFlo still considered one of the best of its kind). These also enable the investigation of markers present in the serum and urine (ELISA, beads arrays flow cytometry and Mass Spectrometry).
Hormone resistant prostate cancer patients as well breast cancer patients who have failed conventional therapy and GBM patients have a relatively poor prognosis and therefore new treatment aimed at stimulating the immune system might prove their last hope.
Dr. Stéphanie McArdle leads the development and assessment of peptide-derived tumour associated antigen vaccines, including a novel and patented prostatic acid phosphatase-derived vaccine (PAP), and a HAGE and NY-ESO1 based vaccines. In addition, two other vaccines are currently being assessed in collaboration with Scancell Ltd (SCIB1 and WT-1-Immunobody®) for the treatment of GBM.
Using pre-clinical tumour model cancers, Stéphanie’s group has already been able to show the efficacy of some of these peptides and are aiming to increase this efficacy of these vaccine using adjuvants such as CAF09 (a PolyIC-based adjuvant) in collaboration with Dr. Dennis Christensen of the Statens Serum Institut, from Denmark and using different deliveyr system such as the one used by Scancell Ltd.
This new and unique PAP-vaccine will be assessed in original preclinical orthotopic and spontaneous prostate cancer (TRAMP) model in collaboration with Prof. Bellone at the University of Milan and Dr Anna Grabowska at Nottingham University.
Moreover, it is known that the functionality of the immune system declines with age ('immune senescence') and that it is also influenced by nutritional and stress status. Given that the gut microflora is altered in individuals over 60 years old and that 70% of our immune system is located in the gut mucosa, it is essential that potential immunotherapeutic strategies are evaluated in pre-clinical models that more closely represent the clinical situation.
The new vaccines comprised of PAP peptide delivered prophylactically or therapeutically will be assessed in aged animals with / without supplementation of their diet with a symbiotic which promotes beneficial gut bacteria. It will thereby determine the synergistic interaction between cancer vaccination and controlled modification of the microbiome in a more relevant mouse model.
Given the important influence of food, stress/emotional status, exercise, and sleep on the immune system in health and in disease, Stéphanie has organised a “Health and Wellbeing” conference which had such a success that a second one is now scheduled for April 12th 2018 at NTU Clifton.
Stephanie is an associate member of the American Association for Cancer Research (AACR) and a member of the European Society of Cancer and Immunotherapy (ESCII).
Talks, seminars and posters:
- "The Identification of Novel Target for immunotherapy". Seminar given as part of the ENACT group. May 2006.
- "The Identification of Immunogenic Tumour derived- Peptides for potential in immunotherapy". Seminar given at Granada as part of the ENACT group. September 2006.
- "Peptides discovery and pre-clinical studies of cancer vaccines". Seminar given at King’s college. Invited by Dr. B. Guinn. March 2007.
- "Identification of novel prostate cancer antigens and Immunogenic Tumour derived- Peptides for potential use in immunotherapy" Seminar given at Southampton. Invited by Prof. Stevenson. May 2007.
- "From the Identification of tumour derived- peptides to Cancer Vaccines". Seminar given in Barcelonna. Invited by Prof. Albericio. January 2008.
- "Discovery of tumour derived peptides". Seminar given to the University of Milan. Januar 2008.
- "HAGE as a potential target for Head and Neck cancer" Seminar given at the University of Pittsburgh (Invited by Dr. R Ferris). April 2008.
- "From Peptides Identification to Cancer Vaccines" Seminar given at the University of Liverpool (Invited by Sarah Coupland). July 2008.
- "Serum free medium one of the keys to successful cytokine ELISPOT assay standardization in a multicenter trial". PIVAC/ESCII conference. Athens. October 2008.
- "HAGE, a cancer/testis antigen expressed in a variety of cancers" M. G. Mathieu; E. Tartour, R. Ferris, C Badoual, Stephen P. Reeder, Bharat Jasani, Robert C. Rees, Stéphanie E.B. McArdle. PIVAC9 Sofia. Oct 2009. (Poster).
- "ELISPOT assays for measuring T cell immunity provide highly reproducible results among different laboratories".
W. Zhang, R. Caspell, M. Ahmad, E. Tartour, N. Haicheur, A. DeLeo, A. Abdelsalam, G. Gaudernack, E.M. Inderberg-Suso, F. Jotereau, N. Labarriere, P. Dudzik, K. Garula, S. Perez, K. Georgakopoulou, E. Naumova, A. Mihaylova, A. Line, K. Silina, N. Aptsiauri, V. Adams, R. Rees, P.V. Lehmann, S. McArdle.
- Cancer Vaccines/Adjuvants/Delivery for the Next Decade conference. Dublin Nov. 2009.
- "HAGE at the crossroad between a biomarker and a target for immunotherapy of cancer" Dr. Stéphanie McArdle. Talk at PIVAC12.
- CIMT conference 2013. Presented two posters: "Development of new prostate cancer vaccine strategies using PAP as target antigen" Jaimy Saif, Morgan Mathieu, Lindy Durrant, Robert Rees, Stephanie McArdle. 2013 and "Characterisation of high and low avidity peptide specific CD8+ T cells using transcriptomic and proteomic tools". Jayakumar Vadakekolathu, David Boocock, Victoria Pudney, Lindy Durrant, Robert Rees, Stephanie McArdle.2013.
Sponsors and collaborators
- Prof. E. Tartour, Head INSERM team : "Immunotherapy and anti-angiogenic therapy in oncology". Located at INSERM U970 Hopital Européen Georges Pompidou, Paris, France.
- Prof. C. Badoual, MD, PhD, Hopital Européen Georges Pompidou; Unité d'Anatomie Pathologique, Paris, France.
- Prof. M. Bellone, Cellular Immunology, Laboratory of Tumour Immunology, Scientific Institute, H. San Raffaele Milan, Italy
- Des Powe, Principal Healthcare Research Scientist, Queens Medical Centre, Nottingham University Hospitals NHS Trust, Nottingham, UK.
- Prof. H. Mehanna, Director of the Institute of Head and Neck Studies and Education, Coventry, UK.
- Dr. Steve Chan, Consultant Oncologist, Department of Clinical Oncology, City Hospital, Nottingham.
- Liverpool with Prof. Clark and Southampton with Barbara Guinn working on vaccines against Leukaemia.
- Dr. Frederick Chen, Consultant Haematologist and Senior Lecturer Immunotherapy and Stem Cell Transplantation, University of Birmingham.
Pre-clinical assessment of PAP-based vaccine hold strong promises for the treatment of prostate cancer. Saif J, Mathieu M, McDonald D, Ahmed M, Vadakekolathu J, Rane S, Durrant L, Rees R, McArdle SE. European Journal of Immunology, under review (4.97).
HAGE (DDX43) is a novel target for combined chemo and immuno-therapies and a biomarker for poor prognosis in breast cancer (BC).Abdel-Fatah TMA, McArdle SE, Johnson C, Moseley P, Ball GR, Pockley AG, Ellis IO, Rees RC, Chan SYT. Annals of Oncology, under review (7.384).
Expression of transglutaminase-2 isoforms in normal human tissues and cancer cell lines: dysregulation of alternative splicing in cancer. Phatak VM, Croft SM, Rameshaiah Setty SG, Scarpellini A, Hughes DC, Rees R, McArdle S, Verderio EA. Amino Acids, 2013, 44:33-44. doi: 10.1007/s00726-011-1127-4. (3.914).
Identification of novel breast cancer-associated transcripts by UniGene database mining and gene expression analysis in normal and malignant cells. Laversin SA, Phatak VM, Powe DG, Li G, Miles AK, Hughes DC, Ball GR, Ellis IO, Gritzapis AD, Missitzis I, McArdle SE, Rees RC. Genes Chromosomes and Cancer, 2013, 52:316-29. doi: 10.1002/gcc.22031. (3.546).
The helicase HAGE expressed by malignant melanoma-initiating cells is required for tumor cell proliferation in vivo. Linley AJ, Mathieu MG, Miles AK, Rees RC, McArdle SE, Regad T. Journal of Biological Chemistry, 2012, 28:13633-43. doi: 10.1074/jbc.M111.308973. (4.651).
Expression of the tumour antigen T21 is up-regulated in prostate cancer and is associated with tumour stage. Miles AK, Rogers A, McCulloch T, Hodi Z, McArdle S, Bishop M, Rees RC. BJU International. 2012, 109:796-805.(3.046).
Cancer/testis antigens for therapeutic use. Mathieu MG, Miles AK, Li G, McArdle SE, Rees RC. J BUON, 2009, 14 Suppl 1:S97-102. (0.761).
ELISPOT assays provide reproducible results among different laboratories for T-cell immune monitoring - even in hands of ELISPOT-inexperienced investigators. Zhang W, Caspell R, Karulin AY, Ahmad M, Haicheur N, Abdelsalam A, Johannesen K, Vignard V, Dudzik P, Georgakopoulou K, Mihaylova A, Silina K, Aptsiauri N, Adams V, Lehmann PV, McArdle S. Journal of Immunotoxicology, 2009, 6:227-34. doi: 10.3109/15476910903317546. (1.571).
Identification of tumour antigens for clinical evaluation. Adakekolathu J, McArdle S, Miles A, Boocock DJ. In Cancer Immunology and Immunotherapy, Edited by Robert C. Rees, Oxford University Press.
- Pre-clinical assessment of cancer vaccine
- Link between the immune system and disease status
- Clinical monitoring (assessing whether the vaccine has induced an immune response in patients)